Guanze Intelligent Medical Information Industry Holding Co. Ltd. has announced its unaudited condensed consolidated interim results for the six months ended 30 June 2025. The company reported a revenue of RMB 31.855 million, down from RMB 40.030 million in the same period in 2024. This decline was primarily attributed to changes in revenue distribution across its product lines. The sales of medical imaging film products, the provision of medical imaging cloud services, and sales of software accounted for approximately 60%, 6%, and 34% of the total revenue in 2025, respectively, compared to 68%, 16%, and 16% in 2024. The cost of sales for the period was RMB 18.472 million, slightly up from RMB 18.150 million the previous year, resulting in a gross profit of RMB 13.383 million, a decrease from RMB 21.880 million in 2024. Other notable financial metrics include other income and gains of RMB 6.140 million, a significant increase from RMB 1.319 million in 2024. The company also reported a decrease in selling and distribution expenses to RMB 5.727 million from RMB 8.451 million, while administrative expenses remained relatively stable at RMB 6.773 million compared to RMB 6.858 million in the previous year. Research and development costs amounted to RMB 2.265 million, up from RMB 1.508 million in 2024. The interim results did not provide specific outlook or guidance for the coming periods. However, there was a notable change in the use of net proceeds from the global offering, reflecting strategic shifts in the company's operations.